Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+353-1-6096000
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Shire (LON:SHP) Frequently Asked Questions
What is Shire's stock symbol?
Shire trades on the London Stock Exchange (LON) under the ticker symbol "SHP."
What price target have analysts set for SHP?
3 brokers have issued 12 month target prices for Shire's shares. Their forecasts range from GBX 4,640 to GBX 4,640. On average, they expect Shire's share price to reach GBX 4,640 in the next twelve months. View Analyst Price Targets for Shire.
What is the consensus analysts' recommendation for Shire?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shire in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Shire.
Has Shire been receiving favorable news coverage?
Media headlines about SHP stock have been trending somewhat positive on Tuesday, InfoTrie reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Shire earned a media sentiment score of 1.1 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Shire.
Who are some of Shire's key competitors?
Some companies that are related to Shire include CSL (CSL), MorphoSys (MOR), BTG (BTG), MorphoSys (MOR), Cronos Group (CRON), Asterias Biotherapeutics (AST), Abcam (ABC), Genus (GNS), Polynovo (PNV), Clinuvel Pharmaceuticals (CUV), Vir Biotechnology (VIR), Concordia International (CXR), Kodiak Sciences (KOD), Immutep (IMM) and Mesoblast (MSB).
What other stocks do shareholders of Shire own?
Who are Shire's key executives?
Shire's management team includes the folowing people:
- Dr. Flemming Ornskov M.P.H., MBA, M.D., MPH, CEO, MD & Exec. Director (Age 60)
- Mr. Thomas J. W. Dittrich, CFO & Director (Age 54)
- Gisele Dion, Chief Accounting Officer
- Mr. Matthew Walker, Head of Technical Operations (Age 54)
- Dr. Andreas Busch Ph.D., Head of R&D and Chief Scientific Officer (Age 55)
How big of a company is Shire?
What is Shire's official website?
How can I contact Shire?
Shire's mailing address is Miesian Plaza 50-58 Baggot Street Lower, Block 2, DUBLIN, D02 HW68, Ireland. The biopharmaceutical company can be reached via phone at +353-1-6096000.
MarketBeat Community Rating for Shire (LON SHP)
MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe SHP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SHP will underperform the S&P 500 over the long term. You may vote once every thirty days.
